Global pharmaceutical company Novartis has become the latest tenant at Lendlease’s Victoria Cross Tower in North Sydney. Novartis ANZ will set up shop across one floor of the building, occupying 1,700 square metres in the mid-rise of the building, Lendlease said Thursday. The skyscraper is more than 30 per cent leased, with 70 percent of…
The High Court won’t hear Bayer’s appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company’s claim the decision has “profound” consequences for drug R&D.
Pharmaceutical giant Lundbeck has resolved its battle with Novartis unit Sandoz over top-selling drug Lexapro, a battle that has raged for years and across multiple courts.
Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.
The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a “commercial outcome for a patentee”.
A judge has slammed Novartis for putting forward four “overlapping” experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a “hot tub”.
The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck’s patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an “untenable” patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.